Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases
Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases
CanProbe focuses on developing new radiopharmaceuticals to meet growing Canadian and global demand for advanced diagnostic and therapeutic molecular probes.
TORONTO, ON (June 22, 2011)-CanProbe, a unique, not-for-profit joint venture to advance the use of medical isotopes for diagnosing and treating cancer and other serious diseases, was announced today by the Centre for Probe Development and Commercialization (CPDC) and the University Health Network (UHN).
- Tagged CanProbe focuses on developing new radiopharmaceuticals to meet growing Canadian and global demand for advanced diagnostic and therapeutic molecular probes., Joint Venture Announced to Expand Use of Molecular Imaging in Ontario for Patient Care and Research of Cancer and Other Serious Diseases
Did you know?
CPDC is one of Ontario’s largest manufacturers of Fludeoxyglucose – the world’s most widely used PET imaging probe.
Learn MoreMolecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.
Learn More
-
The half-life of the fluorine-18 isotope, used to make many PET probes, is only 109.8 minutes. In about a day, the isotopes injected into a patient have either been excreted or have completed their decay.
-
In the last three years, CPDC has introduced three new molecular probes to Ontario for clinical trials in disease diagnosis and drug development.
Learn More
-
CPDC’s Investigator Sponsored Research Program helps researchers move discoveries in molecular probe technology from the lab to the clinic.
Learn More
-
CPDC, along with a national team of experts, is working to develop alternative, non-reactor based sources of medical isotopes to ensure adequate supplies for Canadians.
Learn More
-
CPDC is developing several “orphan probes” to help our health care system diagnose and treat thousands of patients in Canada suffering from certain rare diseases.
-
CanProbe is a new joint-venture company formed by CPDC and University Health Network to meet increasing Canadian and global demand for molecular probes.
Learn More
-
Molecular probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
Learn More
-
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
Learn More
-
During the recent shortage of medical isotopes, CPDC provided substitutes for use in bone scans and imaging kidney function.
Learn More
-
• Over 200 professionals in medical imaging attend CPDC’s Annual Probe Development Workshop to learn about the latest advances in research and application of molecular probes.
Learn More
